Alligator Bioscience publishes financial calendar for 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General ...
Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shar ...
Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB
Alligator Bioscience AB (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation
Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussions Planned reduction of workforce, mainly wit ...
Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation
Transaction valued at €3.5 million The partners have enjoyed a successful discovery collaboration since 2021 Lund, Sweden – Allig ...
Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB
Lund, Sweden, October 31, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in prepa ...
Alligator Bioscience AB reports financial results for the first 9 months of 2024 and for Q3 2024 and provides a business update
Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...